The U.S. National Library of Medicine website publicized the testing of LifeMel honey back in 2005.
This study eventually showed the efficacy of LifeMel, which can be ordered from Vitamin Global here: http://www.vitaminglobal.com/life-mel-honey-120g-tzuf-globus-ltd-p-1619-c-72.html an excellent discount.
This study is not yet open for patient recruitment.
Verified by Rambam Health Care Campus October 2005
Sponsors and Collaborators: | Rambam Health Care Campus zufglobus.com |
Information provided by: | Rambam Health Care Campus |
ClinicalTrials.gov Identifier: | NCT00243165 |
|
Purpose
This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.
Condition | Intervention | Phase |
Breast Cancer | Behavioral: Lifemel honey intake every day |
MedlinePlus related topics: Breast Cancer
Genetics Home Reference related topics: breast cancer
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia
Further study details as provided by Rambam Health Care Campus:
Primary Outcome Measures:
- l Prevention of myelotoxicity-every week during chemotherapy.
Total Enrollment: 60
Study start: November 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Female
Criteria
Inclusion Criteria:
- l breast cancer patient treated with adjuvant chemotherapy
- l PS = 2 or less
Exclusion Criteria:
- l none
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00243165
Georgeta Fried, MD 972-4-8543018 mailto:[email protected]?subject=NCT00243165,%20LifemelCTIL:%20-%20%20Lifemel%20Honey%20to%20Reduce%20Leucopenia%20During%20Chemotherapy
Study chairs or principal investigators
Georgeta Fried, MD, Principal Investigator, Rambam Health Care Campus
More Information
Study ID Numbers: LifemelCTIL
Last Updated: October 20, 2005
Record first received: October 20, 2005
ClinicalTrials.gov Identifier: NCT00243165
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on August 10, 2007